Q2 2025 Earnings Call Transcript August 1, 2025 Fulgent Genetics, Inc. misses on earnings expectations. Reported EPS is $-0.62065 EPS, expectations were $-0.23. Operator: Greetings, and welcome to the ...

Fulgent Genetics Inc (FLGT) reports a 16% increase in core revenue and expands market reach, despite facing GAAP losses and ...

GAAP revenue exceeded expectations in Q2 2025, reaching $81.8 million versus the $76.21 million estimate, Core revenue reached $81.7 million, up 16% year over year. Non-GAAP earnings per share were $0 ...

Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.23 per share. This compares to earnings of $0.15 per share a ...

Fulgent Genetics ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages. It is also at the bottom for Return on Equity, with a negative percentage. Overall, Fulgent ...

Get the cash flow statement for Fulgent Genetics, Inc. (FLGT). Up to 10 years of financial statements. Quarterly or annual. View as % YoY growth or as % of revenue.

Fulgent Genetics, Inc. FLGT shares soared 6.6% in the last trading session to close at $23.31. The move was backed by solid volume with far more shares changing hands than in a normal session.

Fulgent Genetics, Inc. FLGT shares soared 5.8% in the last trading session to close at $21.45. The move was backed by solid volume with far more shares changing hands than in a normal session ...

Fulgent Genetics (FLGT) reported a better-than-expected Q4 earnings report. Read this article to know why FLGT stock remains a Buy.

FLGT is currently sporting a Zacks Rank of #1 (Strong Buy). The Zacks Consensus Estimate for FLGT's full-year earnings has moved 126.30% higher within the past quarter.